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1. Introduction  
Stable gene modification without affecting normal cellular function is a main goal both for 
basic and applied science. Current strategies to achieve stable gene modification are either 
very inefficient (homologous recombination) or very genotoxic (retroviral gene transfer). 
Retroviral vectors derived from oncoretroviruses (murine leukaemia virus - MLV) were the 
first to be widely used for stable gene modifications for gene therapy strategies. They are 
efficient, poorly immunogenic and derived from a non-pathogenic virus. MLV-based 
vectors were also the first ones to show real therapeutic effect by correcting the immune 
system of about 50 patients with four different severe immunodeficiencies X-linked Severe 
Combined Immunodeficiency (SCID-X1), SCID-Adenosine Deaminase Deficiency (SCID-
ADA), Wiskott-Aldrich Syndrome (WAS) and Chronic Granulomatous Disease 
(CGD)(Fischer et al.). However, for most applications therapeutic efficacy were incomplete 
or come together with serious adverse effects such as cell transformation(Neven et al., 2009). 
Different studies have demonstrated that the enhancer elements present in the old 
generation retroviral vectors are important in cell transformation(Montini et al., 2009).  
Therefore, safer integrative vectors are required to replace MLV-based retroviral vectors 
when stable gene modification is required. New vectors for stable expression must consider 
three aspects: 1- efficiency, 2- ectopic or unregulated expression of the transgene and 3- 
genotoxicity (genomic alterations due to vector integrations).  
Probably the most important feature for a vector to reach clinic is efficiency. Gene Therapy 
vectors must be able to efficiently transduce their target cells in order to reach therapeutic 
benefits. High efficiency is especially relevant when the therapeutic protein does not confer 
any positive advantage to the target cells. It is therefore important to keep in mind that very 
safe vectors are of no use if the efficiency does not reach a minimum. We can say that, at 
least for some applications, efficiency is no longer a limitation, and that safety is now the 
main concern.  
The ectopic or unregulated expression of the transgene is other aspect to take into 
consideration. As conventional therapeutic agents, transgenes have a window where and 
when to exert their function. In many diseases, the expression of the affected gene is 
restricted to a particular tissue, to a particular stage of the development and/or in response 
to environmental conditions. The expression of the transgene in non-target cells as well as 
the expression of non-physiological transgene levels may cause toxic or deleterious effects. 
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Therefore, an important safety issue concerning gene therapy is to achieve regulated and/or 
physiological expression of the transgene(reviewed in Toscano et al. 2011). 
Genotoxicity can be defined as harmful actions on the integrity of the genetic material. 
Genotoxic substances are potentially mutagenic or carcinogenic. Integrative vectors are 
genotoxic due to their ability to integrate into the host DNA since vector integration can 
result in alteration of gene expression. In the worst scenario, genotoxicity can cause cell 
transformation and tumor development. Several factors influence vector genotoxicity (Baum 
et al., 2003) such as integration site preference, presence of strong enhancers in the vector, 
weak polyadenylation sites or the integration mechanism. To minimize or eliminate 
genotoxicity problems of integrative vectors we can use safer integration sites (safe harbor), 
block the effect of the vector on the surrounding chromatin (using insulators) or gene 
correction strategies (Figure 1).   
In this chapter we will discuss the most promising strategies that tackle these issues: 1- 
improving safety of retroviral-based vectors, 2- novel non-viral systems to achieve efficient 
transgene integrations, 3- site-specific integrative vector systems and 4- gene correction by 
enhanced homologous recombination.  
2. Improving safety of retroviral-based vectors 
There are two alternative means of improving safety of retroviral-based gene delivery; 1- by 
using alternative retroviruses for vector development and 2-by improving the properties of 
existing retroviral vectors. 
2.1 Alternative retroviral vectors 
One way to improve the safety of stable gene expression is the search for retroviral vectors 
other than the original Moloney-murine-leukemia-virus (MoMLV)-based vectors. 
Retroviruses from two different genus from the retroviridae family have been the main 
focus for the development of new integrative vectors: lentivirus and spumavirus 
2.1.1 Lentiviral-based vectors (LV) 
Lentiviruses are part of the retrovirus family that includes the human immunodeficiency 
virus-1 (HIV-1). Viral vectors are useful vehicles for the delivery of genes into target cells 
and retroviral vectors have become popular because of their ability to integrate into the host 
cell genome and maintain persistent gene expression. Also, the ability to stably transduce 
non-dividing cells has made them one of the best platforms for vector development(Ikeda et 
al., 2003; Cockrell and Kafri, 2007). Lentiviral vectors (LV) offer several advantages over 
gammaretroviral vectors (GVs) (reviewed in Chang and Sadelain, 2007): 1- Transduction 
with LV does not require preactivation of non-dividing cells. They are very efficient for 
stable gene modification of most primary stem cells including neurons, hematopoietic, 
mesenchymal and embryonic stem cells. 2- LV are more resistant to silencing and different 
regulatory elements can be incorporated to minimize influence from neighbouring 
chromatin without substantially affecting vector titre(Ramezani and Hawley, 2010). The 
modifications include utilization of strong internal enhancer-promoter sequences, addition 
of scaffold/matrix attachment regions and flanking the transcriptional unit with chromatin 
domain insulators. 3- The integration “pattern” of LVs is less genotoxic than GVs. Contrary 
to GVs, LVs do not have a preferential insertion next to transcriptional start sites and 
regulatory gene regions. Modlich et al. found(Modlich et al., 2009) that the LVs insertion 
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Fig. 1. Main strategies to achieve safer stable genetic modification for gene therapy 
applications. First generation gammaretroviral vectors (top) contained strong enhancer 
sequences in their LTR backbones that can influence genes located upstream (Gene 1) or 
downstream (Gene 2) of the insertion site. In addition, the promoter activity of the LTR (U3 
region) or that of a strong internal promoter, can also influence activity of downstream 
genes by 3’ readthrough (dashed lines) during the transcription of the transgene. There are 
three main strategies to avoid the potential deleterious effects of stable genetic modification: 
1- Safe harbor. In this direction scientists search for vector systems that integrate in safer 
locations than gammaretroviral vectors. 2- Insulate. Another strategy is to modify the 
integrative vectors by eliminating enhancers from the Long Terminal Repeats (LTRs), by 
using physiological promoters and by the introduction of insulator boundaries that block 
the potential residual effects of the internal promoters on the nearby genes. 3- Gene 
Correction. Recently, a new possibility has come thanks to technologies that dramatically 
increase the efficiency of homologous recombination for gene editing. It is now feasible to 
restore the correct version of almost any mutated gene by the use of zinc finger nucleases or 
meganucleases together with the correct version of the gene. 
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pattern was approximately threefold less likely than the GVs to trigger transformation of 
primary hematopoietic cells. 4- The LVs backbone is more flexible to modifications and 
insertions.  
Of all LVs, HIV-1-based are by far the most used for gene therapy strategies. Other 
lentiviruses commonly used are equine infectious anaemia virus (EIAV), Simian 
immunodeficiency virus(SIV), Feline immunodeficiency virus(FIV) and Bovine 
immunodeficiency virus (BIV): 
Human Immunodeficiency Virus-1 (HIV-1) based vectors. Latest generation LVs are 
devoid of any HIV coding sequences from the original virus (the most commonly used is 
HIV-1). Proteins needed for particle formation and enzymatic activities are supplied in trans 
by separate plasmids encoding Gag, Pol, Env, Tat and Rev proteins (Figure 2). The 
transactivator Tat (generally used in trans to allow vector genome production in producer 
cells) is also dispensable for the generation of fully efficient LV vector particles. In these 
vectors, the Tat-dependent U3 promoter has been replaced by promoters such as the 
cytomegalovirus immediate-early enhancer and promoter (CMVp), resulting in Tat-
independent transcription with no decrease in viral titers(Miyoshi et al., 1998; Delenda, 
2004). 
HIV-1 based LVs efficiently transduce the most important target cells for gene therapists 
(neurons, hepatocytes, dendritic cells). They are probably the most efficient vectors for stem 
cells transduction. They are also safer than other integrative vector systems because they do 
not have integration preference for transcriptional start sites, although they do integrate 
semi-randomly in transcriptionally active areas (Montini et al., 2006). In fact several studies 
have recently demonstrated the lower genotoxicity of LVs compared to oncoretroviral-based 
vectors(Montini et al., 2006; Gonzalez-Murillo et al., 2008). These characteristics have 
prompted scientists to propose LVs as one of the most interesting vectors for gene therapy  
strategies when stable gene expression is required. There are at the moment 29 approved 
clinical trials using lentiviral vectors (http:// www.wiley.com /legacy /wileychi /genmed 
/clinical/) for the treatment of primary immunodeficiencies, adrenoleukodystrophy, 
Parkinson disease, beta-thalasemia, sickle cell disease, Fanconi anemia, AIDS and cancer. 
Since HIV-1 is a highly infectious agent for humans, several groups have though that 
equivalent vectors derived from lentiviruses that are not pathogens for humans could be of 
interest. Vectors based on non-human primates (simian) and non-primates (feline, equine 
and bovine) lentiviruses would theoretically be safer than HIV-1-based vectors, minimizing 
the risk of generating replication-competent virus: 
Simian immunodeficiency virus (SIV)-based vectors. LVs derived from the Simian 
immunodeficiency virus (SIV) have been developed by several groups(Mangeot et al., 2000; 
Hanawa et al., 2004), with safety issues similar to HIV-1 based vectors. They have been used 
for efficient transduction of simian and human hematopoietic stem cells (HSCs)(Sandrin et 
al., 2002). In addition, SIV vectors have been used for correction of CGD in animal 
models(Naumann et al., 2007). They have also demonstrated to facilitate safe and efficient 
retinal gene transfer(Murakami et al.2010) and for the respiratory epithelium (for cystic 
fibrosis treatment) when pseudotyped with the envelope protein of the Sendai 
virus(Mitomo et al.2010). Interestingly, integration site studies have demonstrated that while 
MLV-based vectors integrate predominantly around transcription start sites, SIV integrants 
strongly favoured transcription units and gene-dense regions of the genome without a 
preference for transcription start sites(Hematti et al., 2004).  
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Fig. 2. Schematic representation of HIV-1 provirus DNA and HIV-1 based vector system. In 
the HIV-1 genome (top), the coding regions are flanked by LTRs (5´and 3´) and other cis-
acting elements such as the Primer Binding Site (PBS), the Rev responsive element (RRE) and 
the packaging signal (Ψ). The vector genome (A) does not contain any gene from the 
original virus and the structural and enzymatic proteins required for particle formation, cell 
entry, reverse transcription and integration are supplied by other plasmid constructs  (B and 
C) to allow the formation of a functional particle.  In the majority of the vector constructs, 
the removed viral genes are substituted by an expression cassette consisting of an internal 
promoter driving the expression of a relevant transgene. To produce the viral particles, a set 
of three or four plasmids  coding for the viral genome (A), the env gene (B) and the gag-pol-
rev genes (C) are transfected into a cell line (a packaging cell line) that will be use as a vector 
factory. After transfection, the vector plasmid will produce the vector genome (RNA) and 
the other plasmids will drive the expression and synthesis of the Env, Rev  and Gag-Pol 
proteins required for particle formation. Abbreviations: LTR, viral long terminal repeat; U3, 
LTR 3’ unique element; U5, LTR 5’ unique element; R, repeat element; SA, splice acceptor 
site; SD, splice donor site; ψ, viral RNA packaging signal; ΔU3, self-inactivating deletion in 
U3 region of 3' LTR, cPPT, central polypurine tract; RRE, Rev response element; polyA, 
polyadenylation signal; HEK 293T, human embryonic kidney 293T cells 
Equine infectious anaemia virus (EIAV)-based vectors. Other groups have focused their 
attention to equine infectious anaemia virus (EIAV) based vectors(Mitrophanous et al., 
1999). Although EIAV-based vectors are about 10-fold less efficient in several human cell 
lines than HIV-1 based vectors(Ikeda et al., 2002), they have demonstrated good efficiency 
for treatment of neuromuscular pathologies in animal models(Azzouz et al., 2004; Yip et al., 
2006). In addition, they are able to transduce human HSCs(Siapati et al., 2005) and are very 
efficient in vivo. Several groups have demonstrated their potential applicability for gene 
therapy applications using animal models of neurological disorders, macular dystrophy and 
choroidal neovascularisation.  There is at the moment a Phase I/II study using EIAV vectors 
for the treatment of Parkinson disease (Prosavin) developed by Oxford BioMedica. The 
authors observed an average improvement in motor function of 26%(Trial ID: FR-0041) 
www.intechopen.com
 Gene Therapy - Developments and Future Perspectives 
 
8 
Feline immunodeficiency virus(SIV)-based vectors. Feline immunodeficiency virus has 
been a good choice to develop LVs(Poeschla et al., 1998) as demonstrated by their success in 
several fields (reviewed in Barraza and Poeschla, 2008). However FIV-based vectors are very 
inefficient expressing transgenes in human primary cells due to unknown elements that 
inhibit expression(Price et al., 2002). This low level of transgene expression has hindered the 
wide use of FIV-based vectors for gene therapy strategies. In spite of this, several groups 
have demonstrated the potential of FIV-based vectors in animal models. Grinshpun et al. 
were able to attenuate disease symptoms in a murine model of glycogen storage diseases 
type I (GSD-Ia) by a double neonatal administration protocol(Grinshpun et al.2010). The 
authors extended survival, improved body weight, and decreased the accumulation of liver 
glycogen. Finally, several groups have also demonstrated that FIV integration favoured 
actively transcribed genes (as all retroviral vectors) but the integration preferences were 
more similar to those of primate lentiviruses and distinct from those of moloney murine 
leukemia virus, avian sarcoma leukosis virus, and foamy virus(Kang et al., 2006).  
Bovine immunodeficiency virus based vectors. Another alternative to HIV-1 based vectors 
are the LVs based on bovine immunodeficiency virus (BIV)(Berkowitz et al., 2001; 
Matukonis et al., 2002). BIV-based vectors also transduced a wide panel of gene therapy 
primary targets including unstimulated human HSCs. However, in spite of the generation of 
safer packaging cell lines for BIV-based vectors a few groups have followed these LVs as an 
alternative for gene therapy strategies. 
In summary, the use of non-human LVs is a field of intensive research with some promising 
results in gene therapy. However, based on the published data it is clear that HIV-based 
vectors are still the vector of choice for most applications since they are more efficient and 
have at least the same safety profiles than non-HIV-1 based vectors.  In fact, there is not a 
single study demonstrating that non-human LVs are safer than HIV-based LVs.  
2.1.2 Foamy viral vectors (FVV) 
Foamy viruses (FV) share with other retroviruses the principal genetic order of LTR, gag–
pol–env–accessory genes–LTR, as well as the reverse transcription and integration processes. 
However they complete the reverse transcription process before budding from the cell 
membrane. Another interesting property is the stability of the resulting DNA genome that 
could be the reason for the excellent capability of FV vectors (FVV) to transduce rarely 
dividing cells, such as HSCs. Other important feature is that the viral envelope mediates 
access to virtually any cell type, although the viral receptor is still unknown. The viral 
genome is complex, as it contains not only the gag, pol and env genes, but also genes that 
encode proteins that are not incorporated into the viral particle (bel-1 (tas) and bet).  
FVV were developed over fifteen years ago(Schmidt and Rethwilm, 1995). The majority of 
FVV are based on human foamy virus (HFV) which was derived by a rare zoonotic infection 
of humans by a chimpanzee spumavirus (CFV)(reviewed in Williams, 2008). FVV are highly 
efficient for HSCs transduction, they have a favourable integration profile, can deliver large 
DNA fragments and are derived from a non-pathogenic virus. These properties make them 
a very attractive tool for gene therapy. Novel FVV vectors are devoid of the env gene and the 
internal promoter (Bel1/Tas-independent vectors) and the expression is directed by a 
heterologous human promoter(Trobridge et al., 2002; Bastone et al., 2007).   
For a long time, the low FVV titers have been a major hurdle for FVV clinical applications. 
However, this problem has been overcome and vector titers above 107 per ml are routinely 
produced in different laboratories. Bauer et al(Bauer et al., 2008) described the first 
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successful use of a FVV to treat a genetic disease. The authors used FVV to treat canine 
leukocyte adhesion deficiency (CLAD). Four out of five dogs that received infusion of HSCs 
transduced by a FVV expressing CD18 had complete reversal of the CLAD phenotype for 
more than 2 years. Integration site analysis showed polyclonality of transduced cells and a 
decreased risk of integration near oncogenes as compared to GVs. More recently, Park et al. 
used FFV for conditional expression of short interfering RNAs (siRNAs) in HIV infected 
cells(Park et al., 2009) and their results showed inhibition of HIV replication by more than 
98%. 
2.2 Improvements of first generation retroviral vectors  
In addition to searching for new viruses for vector development, gene therapists are 
continuously trying to improve safety and efficiency of old (MLV-based) and new (HIV-1 
based) retroviral vectors. Below we described the main strategies to achieve better safety 
profiles: 
2.2.1 Self-inactivating (SIN) vectors 
One of the major drawbacks of first generation retroviral vectors has been the use of the 
viral LTR U3 region to drive the expression of the transgene. The U3 contains a strong viral 
promoter and enhancer sequences that have been responsible for the activation of 
downstream host genes leading to transformation and leukemia-like diseases upon insertion 
in hematopoietic stem cells(Baum et al., 2003; Modlich et al., 2009). Therefore, one way to 
improve safety of retroviral vectors is to eliminate the U3 region from the 5’ LTR and to use 
alternative promoters to drive the expression of the transgene. Different authors have 
included different deletions at the U3 region in the 3´ LTR of GVs(Yu et al., 1986; Olson et al., 
1994) and LVs(Miyoshi et al., 1998; Zufferey et al., 1998). During the transduction process, 
reverse transcription transfer this deletion also to the 5´LTR of the proviral DNA. Since the 
U3 region harbor the promoter and enhancer regions required for RNA transcription, this 
mutation not only abrogates potential mobilization of the vector but also reduces 
genotoxicity due to promoter/enhancer interference(Modlich et al., 2006; Modlich et al., 
2009). 
In oncoretroviruses like MVL or SNV, SIN vector development was compromised since the 
U3 from the 3´ LTR is partially involved in the polyadenylation of the viral RNA. Therefore, 
most MLV-derived SIN vectors carry a deletion that still maintain significant transcriptional 
activity in their long terminal repeats (LTRs). Attempts to mutate the TATA box 
dramatically decreased vector titers, presumably due to weak polyadenylation. However in 
LVs, the polyadenylation site is located just upstream of the R region of the LTR and 
therefore tolerate large U3 deletions without functional loss. This has facilitated the use of 
SIN LVs over SIN GVs counterparts. 
2.2.2 Insulators 
Limitations derived from randomly genome insertion of retroviral vectors have two sides, 1- 
possible deleterious effects of vector enhancer elements in host cell gene expression (as 
mentioned above) 2- the effect of chromosomal position in vector expression such as 
transcriptional silencing. Therefore a main goal of gene therapists has been to isolate 
integrative vectors from the host chromatin in such a way that 1- enhancers present in the 
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vector can not influence expression of cellular host genes and 2- that regulatory sequences 
present in the host chromatin can not influence vector expression (Figure 3).  
 
 
Fig. 3. Insulator functions in vector development. A) Vector expression can be enhanced or 
silenced if integrated in a transcriptionally active site or near heterochromatin respectively. 
B) Retroviral vectors can produce the activation or upregulation of poorly active or silent 
genes. This can lead to cell transformation. C). Retroviral vectors can be modified to reduce 
both effects by including insulators boundaries such as HS4 in the backbone. These 
insulators should have two activities;  1- a barrier activity to avoid vector silencing and a 2- 
enhancer blocking activity to block both the effect of chromatin enhancers on vector 
expression and the influence of vectors enhancer on nearby chromosomal genes. 
Insulators are genetic elements near chromatin domain boundaries that function as barriers 
against repressive effects of neighbouring heterochromatin or preventing inappropriate 
activation of a promoter by nearby heterologous enhancers(Bell et al., 2001). The best studied 
vertebrate element is a 1.2-kilobase (kb) fragment containing the chicken β-globin 5´ DNase I 
hypersensitive site 4 (5´HS4) (Bell et al., 1999). This element can protect against position 
effects and also provide enhancer blocking function, two important and separable 
characteristics for an insulator. In addition of HS4, there are several other chromosomal 
elements that function as insulators in different organisms (Gaszner and Felsenfeld, 2006). 
Neff et al.(Neff et al., 1997) hypothesized that the incorporation of chromatin insulator in 
gene therapy vectors should lead to improved safety and expression of therapeutic 
transgenes. However the incorporation of insulator elements may also have undesirable 
consequences such as reduction in viral titre that need to be solved(Hanawa et al., 2009). 
Different insulators have been used to improve safety and expression of various GVs and 
LVs (Emery et al., 2000; Hino et al., 2004; Ramezani et al., 2008). Some authors have combined 
two different elements such as HS4 and BEAD-1 with good results(Ramezani et al., 2008). 
The introduction of these elements into the vector backbone has been shown to decrease 
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genotoxicity and gene silencing(Emery et al., 2000; Hino et al., 2004; Arumugam et al., 2007; 
Robert-Richard et al., 2007; Ramezani et al., 2008; Li et al., 2009). Nienhuis and colleagues 
demonstrated that the inclusion of the insulator in the retroviral construct suppressed 
cellular transformation(Evans-Galea et al., 2007). These important results have pushed gene 
therapists to incorporate these elements into therapeutic vectors, especially when the 
strategy involves gene transfer into stem cells. 
2.2.3 Improved polyadenylation signal 
Although long distance enhancer interactions are the most frequent form of retroviral 
insertional mutagenesis, read-through transcripts (not stopping at the polyadenylation site 
contained in the vector) could be, theoretically, an important safety problem. In retroviruses, 
the polyA motif is contained within the R region of the LTRs and is therefore present in both 
ends of the transcript. To avoid premature termination and polyadenylation in the 5´R 
region, retroviruses have developed weak polyA sites and additional mechanisms of 5 
´polyA site suppression. In addition, SIN vectors lack the majority of the U3 region and this 
increases the probability of read-through. The insufficient termination causes read-through 
of randomly integrated retroviral sequences into cellular genes and contribute to the up-
regulation of cellular proto-oncogenes, potentially triggering malignant transformation 
(Almarza et al.; Schambach et al., 2007). Some groups have shown that the inclusion of 
upstream polyadenylation enhancer elements improves the efficiency of 3′ end mRNA 
processing in GV and LV SIN vectors(Schambach et al., 2007; Hager et al., 2008). The 
resulting vectors not only have improved titer and transgene expression in target cells but 
they also displayed a lower rate of vector mobilization(Koldej and Anson, 2009). Still, 
whether stronger polyA signals in retroviral vectors will result in an improvement of 
biosafety must be further analyzed in animal models.  
3. Novel non-viral systems to achieve efficient transgene integrations 
Although most gene therapy approaches use viral-based vectors to obtain stable integration, 
new non-viral systems may offer some advantages: 1- Viral vector preparations, in 
particular those for clinical use, are very expensive and time consuming. Non-viral vectors 
are less expensive and easy to manufacture. 2- Viral vectors need packaging cell lines for 
their production whereas other non-viral vectors rely on cell free systems with defined 
components. 3- Non-viral vectors are less immunogenic than viral systems(Yant et al., 2000). 
4- Finally, integrative viral vectors have a limited packaging capacity whereas non-viral 
systems can deliver larger DNA fragments (Zayed et al., 2004; Ding et al., 2005). The use of 
non-viral vectors has been limited due to the low efficiency, low rate of integration and 
silencing issues. However there have been important advances in the field in recent years. 
Two main strategies using non-viral systems, transposons and zinc-finger nuleases, are 
having a mayor impact in the area: 
3.1 Transposons 
Transposons (in particular the Sleeping Beauty (SB)) are becoming serious players as gene 
delivery tools. Transposons are DNA sequences that can move from one chromosomal 
location to another utilizing an enzyme named transposase which recognizes two sequences 
flanking the transposon. Any sequence included between the two flanking regions can also 
be mobilized and this characteristic makes the transposons attractive as a gene therapy tools 
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to achieve stable transgene integrations (Figure 4). The mechanism involved behind the 
mobilization of transposons is described elsewhere(Izsvak et al., 2000). Briefly, the inverted 
terminal repeats (ITR) flanking the transposon are recognized by the transposase which 
excises the transposon from the genome (or from a donor plasmid). The transposon is 
inserted into TA sequences in the genome with no preference for genes or intergenic 
regions. This characteristic makes the transposon integration semi-random. It seems that 
they induce low epigenetic changes and no adverse effects have been reported yet(Zhu et 
al.2010). To avoid further transposition events, the expression of the transposase must be 
transient in the target cell. To increase the safety level of transposition, three different ways 
to target SB transposition have been proposed based in the addition of particular DNA 
binding domains to the SB transposase (reviewed in Izsvak et al.2010). 
 
 
ITR: Inverted Terminal Repeats; SB: Sleeping Beauty Transposase.  
Fig. 4. Transposition mechanism of Sleeping Beauty transposon: 1) Delivery of both the SB 
transposon (containing the genetic material to be integrated) and the SB transposase 
(expressed under the control of a constitutive promoter) into the nucleus of the target cell. 
The transposon is flanked by the ITR. 2) In the nucleus, the SB transposase cleaves the 
transposon at the ITR sites. 3) The SB transposase integrates the transgene into any 
accessible TA site in the host genome. 
The development of transposases with higher activity (Sleeping Beauty transposase, SB10 or 
SB100)(Izsvak et al., 2000; Mates et al., 2009) and the new delivery techniques such as 
lipofection, PEI-complexes, hydrodynamic injection, nucleofection or electroporation have 
achieved efficient integration of large fragments of DNA into hard to modify cells, as hESCs 
(Wilber et al., 2007; Mates et al., 2009) or HSCs (Mates et al., 2009). These improvements have 
allowed the use of SB as a real alternative for therapeutic strategies for diseases such as 
junctional epidermolysis bullosa, haemophilia A and B, pulmonary hypertension, 
glioblastoma, inherited tyrosinemia, mucopolysaccharidosis, lung transplantation-
associated complications and B-lymphoid malignancies(Izsvak et al.2010). Indeed, three 
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clinical trials have been approved for the treatment of CD19+ B cell malignancies (Trials ID: 
US-0922, US-1003 and US-1022) using SB transposons. 
4. Site-specific integrative vector systems 
Although the systems mentioned above can reduce genotoxicity of first generation 
integrative MLV-based vectors, they still integrate randomly and have therefore potential 
genotoxicity consequences. Therefore, several groups have dedicated much effort to achieve 
site-specific integration to safer genomic areas. This strategy allows the selection of areas 
that are less rich in genes involved in tumorogenicity and are therefore less likely to cause 
serious side effects. However as we will see in this section, the low efficacy and/or poor 
integration specificity of most site-specific integrative systems have been mayor drawbacks 
of this strategy.   
4.1 Adeno-associated viruses (AAV) 
Adeno-associated virus (AAV) are nonpathogenic, nonenveloped DNA virus that belong to 
the parvovirus family. AAV virions contain a single-stranded DNA genome of only 4,680 
bases, which is flanked by two inverted terminal repeats (ITRs). AAV can replicate in cell 
culture only in the presence of a co-infection by a helper virus, either adenovirus (Ad) or 
herpesvirus (HV). Infection of human cells with wild-type AAV results in site-specific 
integration into the AAVS1 region of chromosome 19 (Kotin et A., 1990). Recombinant AAV 
(rAAV) vectors have an excellent safety record with demonstrated efficiency and safety in 
preclinical studies in thousands of animal studies. AAV have been very successful for human 
gene therapy strategies in liver, muscle and eye (reviewed in Rolling, 2010; Tang et al., 2010); 
van der Laan et al., 2011), however, the therapeutic benefits did not correlate with site-specific 
vector integration. Expression of Rep78 or Rep68 is necessary for targeted integration of AAV-
derived DNA and, in its absence, AAV genome is kept as episomal DNA or integrates by 
nonhomologous recombination at random locations. The limited DNA cargo capacity of AAV 
particles and the need to maintain the rep ORF, precludes the use of AAV itself as a site-specific 
integration vector. It is now well established that the rAAV vector genomes exist in a 
predominantly episomal form and that transduced dividing cells lose expression with time 
(Miao et al., 1998). However, the non-specific integration of rAAV vectors allow stable 
expression in several cell types, including hematopoietic stem cells (Maina et al., 2008) and 
germ line stem cells (Honaramooz et al., 2008). AAV vectors have been used in preclinic 
studies of immunodeficiencies like CGD, a heterogeneous group of disorders arising from 
molecular lesions in the genes encoding a phagocyte-specific enzyme system, the NADPH-
oxidase. Vectors based on AAV with a functional copy of the p47phox gene have been used to 
transduce EBV-immortalized B cells derived from patients with CGD, achieving a stable 
expression of protein and restoration of NADPH-oxidase function in these cells for 3 months 
without selection (Thrasher et al., 1995). In summary, although rAAV can achieve stable 
integration in certain cell types, this integration is random as for retroviral vectors and can 
cause mutations (Nakai et al., 2003) and tumor development (Donsante et al., 2007). Therefore, 
although AAV vectors can achieve stable gene expression, they are not safer than other 
integrative systems such as GVs or LVs.  
4.2 AAV Hybrid vectors 
AAV hybrid viral vectors utilize the cis- (ITRs) and trans- (Rep68/78) acting components of 
AAV viruses to specifically target transgenes into the AAVS1 integration site at 
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chromosome 19. This technology has opened the possibility of integrating large DNA 
sequences in a site specific fashion with the aim of minimizing genotoxicity. AAV-Hybrid 
vectors based on plasmids, baculovirus, Ad and HSV can potentially accommodate genetic 
material of more than 30.000 base pairs (Smith, 2008). Two factors are limiting in this 
system, the first one is the delivery efficiency of the transgene flanked by the AAV ITRs and 
the Rep68/78 to the target cells and the second is the Rep68/78 protein toxicity. In fact, Rep 
proteins down-regulate the expression c-H-ras, c-fos, c-myc, and c-sis and can inhibit the 
proliferation of some cell lines. In addition Rep-mediated integration at AAVS1 can lead to 
nonspecific genomic rearrangements at the same locus. The frequency and severity of these 
undesired effects might be attenuated or suppressed by setting a time limit to the activity of 
Rep proteins in target cells. This has been achieved by trasfecting Rep proteins or rep mRNA 
directly, by using inducible promoters or by construction of regulated Rep chimeras.  
4.2.1 Plasmid/AAV 
Based on data obtained from AAV integration process, several groups have designed a site-
specific integration system based in two plasmids: an integrating plasmid containing AAV 
ITRs and the second providing the AAV Rep proteins. Co-transfection of both plasmids in 
293T cells achieved site-specific integration in the AAVS1 integration site. This system has 
achieved stable expression in several cell lines including hematopoietic cells(Howden et al., 
2008). However the low plasmid transfection efficiency in primary cells has limited its use in 
gene therapy applications. New gene delivery technologies will certainly improve the 
results obtained with this system. 
4.2.2 Baculovirus/AAV  
The baculoviruses are a family of large, double stranded DNA (80-180kb), enveloped viruses 
that infects only invertebrates. The baculovirus Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV)-based vectors have recently been developed as a new tool 
for gene therapy (reviewed in Hu et al. 2010). Latest generation of baculovirus vectors 
systems are safe, easy to use and amenable to scale up. Baculovirus vectors are able to 
transduce a wide range of human cell lines, including primary cells such as bone marrow 
fibroblasts, neural cells, hepatocytes and mesenchymal stem cells. Zeng and co-
workers(Zeng et al., 2007) have demonstrated their ability to transduce human embryonic 
stem cells without altering their characteristics. The hybrid vectors contained three 
promoters, one driving the expression of the complete baculovirus genome, the second 
expressing eGFP and the third (AAVp5) driving the expression of Rep78. However, in spite 
of their potential, the usefulness of this technology for stable integrations of transgenes into 
stem cells has not yet been achieved.  
4.2.3 Adenovirus/AAV 
Adenoviruses (Ad) are non-enveloped non-integrative viruses composed of a nucleocapsid 
and a double-stranded linear DNA genome. There are 51 immunologically distinct human 
Ad serotypes, however, the subgroup C serotypes 2 or 5 are the most used for vector 
development. The wild type Ad genome is approximately 35 kb of which up to 34 kb can be 
replaced with foreign DNA in the helper dependent (HD) Ad gutless vector. Ad vectors can 
mediate high level of transduction in a wide variety of both quiescent (post-mitotic cells) 
and proliferating cells. However, since they are non-integrating, transgene expression in 
dividing cells is progressively lost. The development of Ad/AAV hybrid vectors(Lieber et 
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al., 1999; Recchia et al., 1999) aim to increase the integration efficiency. Clearly, a vector that 
combines the advantages of Ad (high titer, high infectivity, and large capacity) with the 
integration capability of AAV would be advantageous for gene therapy. The Ad/AAV 
hybrid vectors system requires two Ad vectors; one containing the Ad-ITRs, the Ad 
packaging signal and the AAV-ITRs flanking the DNA of interest and a second one 
expressing the AAV Rep68/78 protein (Figure 5).  
 
 
Fig. 5. AAV/Adenoviral hybrid vectors. The AAV/Ad hybrid vectors combine the large 
packaging capacity of Ad with the site-specific integration potential of AAV vectors. Either 
AAV Rep68 or Rep78 proteins are sufficient to mediate insertion of AAV-ITR-containing 
DNA into the AAVS1 on chromosome 19.  By including the AAV-ITR into the adenoviral 
backbone and expressing Rep68 or Rep78 we can achieve integration of the adenoviral vector 
into the AAVS1 site. Only DNA sequences flanked by the AAV-ITR will be integrated into 
the chromosome 19. The most efficient systems use an additional adenoviral vector to 
produce the Rep68/78 proteins required for specific integration. 
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Although Ad vectors harboring transgenes flanked by AAV-ITRs can be produced easily, 
the production of Ad expressing Rep68/78 is more complicated due to the Rep68/78 
inhibition of Ad replication. Recchia and co-workers (Recchia et al., 1999) tackled this 
problem by expressing Rep78 gene under the control of promoters with low activity in the 
packaging cells. Another relevant issue is that transduction of stem cells with first 
generation Ad vectors is associated with toxicity due to viral gene expression. Therefore 
helper dependent (HD) Ad vectors depleted of all viral genes should be used for stem cells 
transduction. In fact most Ad/AAV hybrid systems are based on HD Ad vectors which 
have demonstrated their ability to stably express several transgenes by specific integration 
into the AAVS1 integration site, both in vitro and in vivo achieving expression of therapeutic 
levels of Factor VIII in hemophilia A mice (Gnatenko et al., 2004) and of dystrophin in mdx 
mice (Goncalves et al., 2005).  
Although the Ad/AAV hybrid system has achieved specific integration into the AAVA1 
site, the efficiency is far from 100%. Recently Wang et al(Wang and Lieber, 2006) 
demonstrated that Ad/AAV can achieve up to 30% efficiency of stable expression (30% of 
the cloned cells have stable expression of the transgene). In addition only 30% of these 
clones stably expressing the transgene were integrated at the AAVA1 site while in the other 
70% the stable expression was a consequence of homologous recombination or random 
insertion. Further knowledge of the mechanism involved in site specific integration into the 
AAVA1 site and the processes involving homologous recombination will certainly increase 
the potential of these vectors. 
4.2.4 Herpesvirus/AAV 
Herpesvirus (HSV) are a large family of enveloped DNA virus that cause diseases in 
animals, including humans. Their genome is composed of large (over 150kb) double 
stranded linear DNA encoding 100-200 genes. The DNA is packed by an icosahedral protein 
structure or capsid that is surrounded by a lipid bilayer membrane (envelope). HSV-1 have 
several characteristics that make them a promising gene delivery vector such as their 
capacity to package large amounts of heterologous DNA (over 100kb), their ability to 
establish persistent, lifelong infections and a broad range of cell tropism including dividing 
and non-dividing cells (reviewed in Berto et al., 2005)). An important property of HSV-1-
based vectors is the ability to deliver a complete genomic locus, in which the native 
promoter and regulatory regions drive and control expression of the transgene. However 
first and second generation HSV-1 based vectors require the expression of regulatory viral 
proteins that hinder their applicability into the clinic. To tackle this problem several authors 
developed HSV amplicon vectors, bacterial plasmids that contain only the origin of 
replication and the DNA packaging/cleavage signal from HSV-1. These HSV amplicon 
vectors are dependent on helper virus function to provide the replication machinery and 
structural proteins necessary for packaging the amplicon vector DNA into viral particles. 
Helper packaging function is provided by a replication-defective virus or by packaging 
methods using a set of 5 overlapping cosmids or bacterial artificial chromosomes (BAC) that 
encode the entire HSV genome.  
The HSV/AAV hybrid vectors combine the high efficiency and large transgene capacity of 
HSV-1 amplicon vectors with the potential for site-specific chromosomal integration of AAV 
vectors. The hybrid HSV/AAV vectors contain the origin of DNA replication and the DNA 
cleavage/packaging signal of HSV-1 and a transgene (ie lacZ reporter gene) under the 
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control of a desired promoter flanked by AAV inverted terminal repeat (ITR) sequences. 
HSV/AAA hybrid vectors are relatively inefficient in achieving stable expression of the 
trasngene (2-20% depending of the cell line and the vector system), however they are one of 
the most efficient systems to direct site-specific integration (50-70% of stably-expressing 
cells). One of the main advantages of HSV/AAV hybrid vectors is their capability to achieve 
site-specific integration of up to 100kb in a significant proportion of transduced cells. 
Although HSV/AAV vectors have been successful in animal models of Ataxia-
Telangiectasia(Cortes et al., 2003; Cortes et al., 2008) they still have some safety concerns such 
as the low efficiency in important target cells (HSCs) and the random integrations observed 
in over 40% of stably expressing cells. 
4.3 Site-specific integrases 
Another alternative used by gene therapists to achieve site-specific integration of 
therapeutic genes is based on naturally occurring site-specific integrases recognizing specific 
target in the human genome. One of such enzymes is the Streptomyces bacteriophage derived 
phiC31 integrase, which mediates site-specific integration of plasmid DNA (pDNA) into 
mammalian host genomes(Thyagarajan et al., 2001; Olivares et al., 2002). This integrase can 
insert large DNA elements (over ten kilobases in size) containing an attB sequence into 
genomes containing attP sites. Importantly, this integrase recognizes sequences in the 
mammalian genome termed pseudo-attP sites(Sclimenti et al., 2001). These pseudo attP sites 
are also present in the human genome and can mediate efficient phiC31 -integrase-mediated 
integration (Figure 6). In addition, directed evolution has rendered new integrases specific 
for pseudo attP sites located at human chromosome 8(Sclimenti et al., 2001). Using this 
technology several authors have shown the potential of the phiC31 integrase system for the 
treatment of lung diseases(Aneja et al., 2007) and human skin diseases(Ortiz-Urda et al., 
2002). Others have shown long-term transgene expression in liver(Olivares et al., 2002) and 
retina(Chalberg et al., 2005) .  
 
 
Fig. 6. Site specific integration of phiC31 integrase in the human genome. PhiC31 integrase 
mediates the integration of a plasmid containing an attB site and the transgene  into pseudo-
attP sites at the human genome. Once integrated the donor sequence is flanked by attR and 
attL sequences. 
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However safety of phiC31 integrase-mediated integration has not yet been studied in detail. 
Several authors have found imprecise integrations into pseudo-attP sites resulting in DNA 
deletions(Thyagarajan et al., 2001; Ehrhardt et al., 2005) and others have found that the 
phiC31 integrase may cause chromosomal instability(Held et al., 2005; Chalberg et al., 2006; 
Liu et al., 2006). In any case, no serious adverse events have occurred so far in animal models 
and therefore further studies are required to assess the safety of this vector system. 
4.4 Zinc-finger DNA binding domains-transposases chimeras  
Other attempts to target DNA integration to specific sites have used transposases from 
sleaping beauty (SB)(Wilson et al., 2005) or piggyback(Wu et al., 2006) transposons. SB-based 
vector systems have been successful in several preclinical models(reviewed in Izsvak et al., 
2010). However, first generation transposons have two major limitations; the low rate of 
integration compared to viral-based vectors and the nonspecific integration of the transgene. 
The incorporation of DNA-binding domains into the transposase can potentially increase 
efficiency and result in site-specific integration. SB transposase fused to the Sp1 zinc finger 
DNA binding domain has achieved specific integration in sp1(Wilson et al., 2005). Similarly, 
Wu et al(Wu et al., 2006)  demonstrated targeted integration to gal4 sites by coupling Gal4 
DNA-binding domain to piggyback transposase. As proof-of-principle, these results are 
promising while further work is needed to provide more information about non-desired 
integrations and to target other integration sites. Targeting sp1 or gal4 sites is not, in 
principle, the most appropriate strategy for most gene therapy applications since they could 
affect gene expression of a wide range of relevant genes. 
4.5 Zinc-Finger Nucleases for site directed integration 
In addition to the use of ZFN for gene repair (see below in point 5), ZFN can be use to 
introduce expression cassettes specifically into already identified “safe harbors”, which are 
particular locations in the genome where the insertion of exogenous DNA is theoretically 
less genotoxic. This is the case for the adeno-associated visus integration site (AAVS1) locus 
in human or the ROSA26 locus in mouse. This strategy has already been utilized by some 
groups(DeKelver et al.; Hockemeyer et al., 2009) and tested in cell lines including hESC. This 
strategy overcomes the need to develop ZFNs for a particular mutation for each particular 
disease, which nowadays is an expensive, cumbersome and time consuming process.  
5. Gene correction by enhanced homologous recombination 
Gene correction aims to repair a defective gene directly in the cellular genome by gene 
targeting, a process in which a DNA molecule introduced into a cell replaces the 
corresponding chromosomal segment by homologous recombination. This is certainly the 
more logic way to cure primary immunodeficiencies since the “in situ” correction of the 
mutation(s) will restore normal physiological gene function and therefore will warrant 
sustained and regulated expression of the repaired gene through its endogenous promoter. 
However, site-specific engineering of the human genome has been limited by the low 
frequency of homologous recombination (HR), by the requirement of sophisticated targeting 
vectors and by the use of drug selection. Recently, improvements in DNA-delivery 
technology and in the development of customized zinc-finger-nucleases (ZFN)(reviewed in 
Cathomen and Joung, 2008) have awaken new interest in this technology for its use in gene 
therapy approaches. 
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Fig. 7. Gene targeting using zinc finger nucleases. A) Zinc finger nucleases are chimeric 
proteins containing a zinc finger domain specific for a 9-12 nucleotide sequences and a Fok 1 
nuclease domain that requires dimerization to cut DNA. For targeting specific DNA 
sequences the system require two ZFNs (right and left) each recognizing a 12 nucleotide 
sequence separate by a 4-6 nucleotide sequence. B) Once the zinc finger binds to its targets, 
the nuclease cleaves the DNA creating a double strand break C) The double strand break 
induces the own cell repair mechanisms to resolve the damage. The two main processes are 
non-homologous end joining  (NHEJ) and homologous recombination directed repair. If a 
donor DNA (with homologous sequences) is not available the break is repaired by NHEJ 
yielding small deletions or additions. This process can be harnessed to induce gene 
disruption. When a homologous DNA sequence is present, the cell can repair the break by 
homologous recombination. The transfection of donor DNA with homologous regions 
together with the zinc finger nucleases allows gene editing by including the desired 
sequences inside the homologous regions. This system can be used to introduce small 
changes for gene repair or bigger changes to promote gene addition.  
Zinc finger nucleases can be considered custom-designed molecular scissors. ZFNs combine 
the non-specific cleavage of an endonuclease (FokI) with the specific recognition properties 
of zinc finger proteins (ZFPs) to cut at the desired chromosomal locus inside the 
cells(Ashworth et al., 2006)(Figure 7). A single zinc finger domain recognizes three 
consecutive nucleotides. The ZFN is composed by a ZFP containing three to four zinc finger 
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domains, which recognize a 9 to 12 nucleotide sequence, and the FokI domain. The DNA 
cleavage by FokI requires dimerization(Miller et al., 2007) and therefore two different ZFPs 
must properly bind to the DNA side-to-side from the breaking point. Once the target DNA 
has been cut, the cells´ own repair machinery resolves the break by non homologous end 
joining (NHEJ) or homologous recombination (HR) depending on the absence or presence of 
a donor DNA (Figure 7). When not present, the DNA break is repaired by NHEJ and when a 
donor DNA is present HR is the main mechanism.  
Using this principle, ZFNs have proven invaluable for stimulating homology-directed gene 
repair in a variety of cell types. The accuracy and high efficiency of the HR process 
combined with the ability to design ZFNs that target most DNA sequences make this 
technology a powerful tool for gene correction. Recent results have shown that ZFNs can be 
used to create targeting frequencies from 5-50% in the absence of selection in several cell 
lines(Urnov et al., 2005; Miller et al., 2007) including primary T cells(Perez et al., 2008), 
hematopoietic stem cells(Lombardo et al., 2007), mesenchymal stem cells(Benabdallah et al.) 
and embryonic stem cells(Hockemeyer et al., 2009).  
Recently, ZFNs have shown in vivo correction of a humanized mouse model of hemophilia B 
(Hojun et al., 2010). In this work, in vivo administration of AAV expressing the ZFNs 
achieved cleavage of the target site in up to 45% of the hepatocytes. When co-administered 
together with donor plasmids containing the correct version of the gene the authors 
achieved circulating F.IX levels 2-7% of normal which was enough to obtain phenotypic 
correction of the defect of clot formation.  
The ZFNs have also been used in clinic not to correct a mutated gene but to disrupt the 
expression of a disease-causing-gene. Several clinical trials have been approved to use  
ZFNs with this aims: Reik et al have proposed the use of Zinc finger nucleases targeting the 
glucocorticoid receptor of allogenic transgenic Il13-expressing CTLs with idea to make them 
resistant to glucocorticoids for the treatment of glioblastoma (ClinicalTrials.gov Identifier: 
NCT01082926). Other two groups have targeted CCR5 for the treatment of HIV, used as a 
co-receptor for HIV entrance (Holt et al.; Perez et al., 2008) (ClinicalTrials.gov Identifier: 
NCT00842634 and NCT01044654).  
6. Conclusion 
Stable gene modification without affecting normal cellular function is a main goal both for 
basic and applied science. Most gene therapy targets, such as inherited, infectious and 
degenerative diseases will benefit from a safe and efficient integrative system. Old strategies 
to achieve stable gene medication are either very inefficient (homologous recombination) or 
very genotoxic (gammaretroviral gene transfer). Retroviral vectors derived from 
gammaretroviruses (the most widely used vectors for gene therapy studies) were the only 
alternative for stable gene modification for years. They were the first vectors to show real 
therapeutic effect but they also showed a high risk of cellular transformation, producing 
leukaemia in several patients. As we have seen in this chapter, a variety of different 
strategies are under development aiming to achieve efficient and stable gene modification 
with minor or undetected genomic alterations. Although exciting new non-viral 
technologies have been developed that efficiently integrate the genome into safe harbors in 
the genome, we are still investigating the real safety benefits of these technologies. By taking 
together efficiency and safety we can, at this moment, argue in favour of improved viral 
technologies as the better tools for clinical use. New viral vectors are more efficient and safer 
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than first generation gammaretroviral vectors used in previous clinical trials. In particular, 
latest generation of lentiviral vectors have seen a major boost and we are convinced that 
new exciting clinical results will be coming in the next few years. 
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